Emerging therapies for osteoporosis

Expert Opinion on Emerging Drugs

Volumn 5, Issue 1, 2000, Pages 1-43

  Gowen, Maxine ^a   Emery, John G ^a   Kumar, Sanjay ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

antiresorptives; bisphosphonates; bone formation; calcitonin; oestrogen; osteoblasts; osteoclasts; osteoporosis; parathyroid hormone; SERMs; therapeutic targets

Indexed keywords

17ALPHA HYDROXY 11 METHYLENE 19 NORPREGNA 4,15 DIEN 20 YN 3 ONE; ALENDRONIC ACID; ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CLODRONIC ACID; COLECALCIFEROL; CONJUGATED ESTROGEN; DROLOXIFENE; ELCATONIN; ESTRADIOL; ETIDRONIC ACID; FC 1271; ISOFLAVONE DERIVATIVE; LASOFOXIFENE; MIRACALCIN; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; SECALCIFEROL; TIBOLONE; TRIMGESTERONE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; BONE DENSITY; BONE METABOLISM; BONE REMODELING; BONE TURNOVER; CLINICAL TRIAL; COST OF ILLNESS; ESOPHAGITIS; HEARTBURN; HOT FLUSH; HUMAN; HYPOCHOLESTEROLEMIA; LEG CRAMP; MAJOR CLINICAL STUDY; META ANALYSIS; NAUSEA; OSSIFICATION; OSTEOPOROSIS; PHASE 1 CLINICAL TRIAL; REVIEW; THROMBOEMBOLISM;

EID: 0033995217     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.5.1.1     Document Type: Article

References (154)

1. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am. J. Med. (1993) 94:646-650.
2. KANIS JA, MELTON LJ 3RD, CHRISTIANSEN C et al.: The diagnosis of osteoporosis. J. Bone Miner. Res. (1994) 9:1137-1141.
3. BAUER DC, SKLARIN PM, STONE KL et al.: Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures. J. Bone Miner. Res. (1999) 14:1404-1410.
4. MELTON LJ 3RD: How many women have osteoporosis now? J. Bone Miner. Res. (1995) 10:175-177.
5. MELTON LJ 3RD, KAN SH, FRYE MA et al.: Epidemiology ofvertebral fracturesinwomen. Am. J. Epidemiol. (1989) 129:1000-1011.
6. JENSEN GF, CHRISTIANSEN C, BOESEN J et al.: Epidemiology of postmenopausal spinal and long bone fractures. A unifying approach to postmenopausal osteoporosis. Clin. Orthop. Rel. Res. (1982) 166:75-81.
7. O'NEILL TW, FELSENBERG D, VARLOW J et al.: The prevalence of vertebral deformity in European men and women: the European vertebral osteoporosis study. J. Bone Miner. Res. (1996) 11:1010-1018.
8. COOPER C, O'NEILL T, SILMAN A: The epidemiology of vertebral fractures. European vertebral osteoporosis study group. Bone (1993) 14(Suppl. 1):S89-S97.
9. BARRETT-CONNOR E: The economic and human costs of osteoporotic fracture. Am. J. Med. (1995) 98(Suppl. 2A):S3-S8.
10. RAY NF, CHAN JK, THAMER M et al.: Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J. Bone Miner. Res. (1997) 12:24-35.
11. CUMMINGS SR, RUBIN SM, BLACK D: The future of hip fractures in the United States. Numbers, costs, and potential effects of postmenopausal estrogen. Clin. Orthop. Rel. Res. (1990) 252:163-166.
12. EDDY DM, JOHNSTON CC: Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Introduction. Osteoporos. Int. (1998) 8:S7-S80.
13. THE WRITING GROUP FOR THE PEPI TRIAL: Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. J. Am. Med. Assoc. (1996) 276:1389-1396.
14. SPEROFF L, ROWAN J, SYMONS J et al.: The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. J. Am. Med. Assoc. (1996) 276:1397-1403.
15. HULLEY S, GRADY D, BUSH T et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) research group. J. Am. Med. Assoc. (1998) 280:605-613.
16. BERESFORD SA, WEISS NS, VOIGT LF et al.: Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet (1997) 349:458-461.
17. COLDITZ GA Hormones and breast cancer: evidence and implications for consideration of risks and benefits of hormone replacement therapy. J. Women's Health (1999) 8:347-357.
18. WALSH BW, KULLER LH, WILD RA et al.: Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. J. Am. Med. Assoc. (1998) 279:1445-1451.
19. ETTINGER B, BLACK DM, MITLAK BH et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. J. Am. Med. Assoc. (1999) 282:637-645.
20. CUMMINGS SR, ECKERT S, KRUEGER KA et al.: The effect of raloxifene on risk of breast cancer in postmeno-pausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. J. Am. Med. Assoc. (1999) 281:2189-2197.
21. BEARDSWORTH SA, KEARNEY CE, PURDIE DW Prevention of postemenopausal bone loss at lumbar spine andupperfemur with tibolone:atwo yearrandomised controlled trial. Br. J. Obstet. Gynecol. (1999) 106:678-683.
22. GENAZZANI AR, BENDEK-JASZMANN LJ, HART DM et al.: Org OD 14 and the endometrium. Maturitas (1991) 13:243-251.
23. ADACHI JD, BENSEN WG, BROWN J et al.: Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N. Engl. J. Med. (1997) 337:382-387.
24. CUMMINGS SR, BLACK DM, THOMPSON DE et al.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. J. Am. Med. Assoc. (1998) 280:2077-2082.
25. HARRIS ST, WATTS NB, GENANT HK et al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteopo rosis-a randomized controlled trial. J. Am. Med. Assoc. (1999) 282:1344-1352.
26. LIN JH: Bisphosphonates: a review of their pharma-cokinetic properties. Bone (1996) 18:75-86.
27. MURRILLS RJ, SHANE E, LINDSAY R et al.: Bone resorp-tion by isolated human osteoclasts in vitro: effects of calcitonin. J. Bone Miner. Res. (1989) 4:259-68.
28. PEICHL P, RINTELEN B, KUMPAN W et al.: Increase of axial and appendicular trabecular and cortical bone density in established osteoporosis with intermittent nasal salmon calcitonin therapy. Gynecol. Endocrinol. (1999) 13:7-14.
29. KOHNO T, MURASUGI N, SAKURAI H et al.: A sandwich transfer enzyme immunoassay for salmon calcitonin: determination of the bioavailability of intranasal salmon calcitonin in human. J. Clin. Lab. Anal. (1997) 11:380-387.
30. NOTOYA K, YOSHIDA K, TSUKUDA R et al.: Effect of ipriflavone on expression ofmarkers characteristic of the osteoblast phenotype in rat bone marrow stromal cell culture. J. Bone Miner. Res. (1994) 9:395-400.
31. GENNARI C, ADAMI S, AGNUSDEI D et al.: Effect of chronic treatment with ipriflavone in postmeno-pausal women with low bone mass. Calcif. Tissue Int. (1997) 61(Suppl. 1):S19-S22.
32. CHAPUY MC, ARLOT ME, DUBOEUF F et al.: Vitamin D3 and calcium to prevent hip fractures in the elderly women. N. Engl. J. Med. (1992) 327:1637-1642.
33. MAMELLE N, MEUNIER PJ, DUSAN R et al.: Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet (1988) 2:361-365.
34. RIGGS BL, HODGSON SF, O'FALLON WM et al.: Effect of fluoride treatment on the fracture rate in postmeno-pausal women with osteoporosis. N. Engl. J. Med. (1990) 322:802-809.
35. KLEERKOPER M: Fluoride: the verdict is in, but the controversy lingers. J. Bone Miner. Res. (1996) 11:565-567.
36. FRANCIS RM. The calcium controversy. In: Osteoporosis 1990. Smith R (Ed.),. Royal College of Physicians of London, London, UK (1990):125-133.
37. JOHNSTON CC, JR., MILLER JZ, SLEMENDA CW et al.: Calcium supplementation and increases in bone mineral density in children. N. Engl. J. Med. (1992) 327:82-87.
38. YAFFE K, SAWAYA G, LIEBERBURG I et al.: Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. J. Am. Med. Assoc. (1998) 279:688-695.
39. OGER E, SCARABIN PY: Assessment of the risk for venous thromboembolism among users of hormone replacement therapy. Drugs Aging (1999) 14:55-61.
40. GENANT HK, LUCAS J, WEISS S et al.: Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. Arch. Int. Med. (1997) 157:2609-2615.
41. STUDD J, ARNALA I, KICOVIC PM et al.: A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures. Obstet. Gynecol. (1998) 92:574-579.
42. SAAG KG, EMKEY R, SCHNITZER TJ et al.: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N. Engl. J. Med. (1998) 339:292-299.
43. ORWOLL E, ETTINGER M, WEISS S et al.: Alendronate treatment of osteoporosis in men. J. Bone Miner. Res. (1999) 14(Suppl. 1):S184.
44. ETTINGER B, PRESSMAN A, SCHEIN J et al.: Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J. Managed Care Pharm. (1998) 4:488-492.
45. WATTS NB, HARRIS ST, GENANT HK et al: Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N. Engl J. Med. (1990) 323:73-79.
46. PETER CP, KINDT MV, MAJKA JA: Comparative study of bisphosphonates to damage gastric mucosa of rats. Dig. Dis. Sci. (1999) 43:1009-1015.
47. DAVIS SM, BROWN TR: Use of etidronate in the treatment of postmenopausal osteoporosis. J. Pharm. Technol. (1994) 10:102-105.
48. FILIPPONI P, PEDETTI M, FEDELI L et al.: Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy. J. Bone Miner. Res. (1995) 10:697-703.
49. OVERGAARD K, RIIS BJ, CHRISTIANSEN C et al.: Effect of salcatonin given intranasally on early postmenopausal bone loss. Br. Med. J. (1989) 299:477-479.
50. ADAMI S, BUFALINI L, CERVETTI R et al: Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over two years. Osteoporos. Int. (1997) 7:119-125.
51. KUIPER G, ENMARK E, PELTOHUIKKO M etal: Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA (1996) 93:5925-5930.
52. MOSSELMAN S, POLMAN J, DIJKEMA R: ER-(3-Identification and characterization of a novel human estrogen receptor. FEBS Lett. (1996) 392:49-53.
53. TREMBLAY GB, TREMBLAY A, COPELAND NG et al: Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor (3. Mol. Endocrinol. (1997) 11:353-365.
54. FLEISCH HA: Bisphosphonates-preclinical aspects and use in osteoporosis. Ann. Med. (1997) 29:55-62.
55. SEEMAN E, TSALAMANDRIS C, BASS S et al: Present and future of osteoporosis therapy. Bone (1995) 17(Suppl 2):S23-S29.
56. DEMPSTER DW, COSMAN F, PARISIEN M et al.: Anabolic actions of parathyroid hormone on bone. Endocrinol. Rev. (1993) 14:690-709.
57. COSMAN F, LINDSAY R: Is parathyroid hormone a therapeutic option for osteoporosis-a review of the clinical evidence. Calcif. Tissue Int. (1998) 62:475-480.
58. MARIE PJ, ARLOT ME, BRAILLON P et al: A new agent containing strontium (S 12911) increases bone mass in normal and ovariectomized rats. J. Bone Miner. Res. (1991) 6:S249.
59. KE HZ, CHEN HK, SIMMONS HA et al: Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model. Bone (1997) 20:31 39
60. ROSATI RL, JARDINE PD, CAMERON KO et al: Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J. Med. Chem. (1998) 41:2928-2931.
61. TAKEUCHI M, SAKAMOTO S, YOSHIDA M et al: Studies on novel bone resorption inhibitors. I. Synthesis and pharmacological activities of aminomethylene- bisphosphonate derivatives. Chem. Pharm. Bull (1993) 41:688-93.
62. THIEBAUD D, BURCKHARDT P, KRIEGBAUM H et al.: Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am. J. Med. (1997) 103:298-307.
63. GEDDES AD, SOUZA D, EBETINO FH et al: Bisphos-phonates: structure-activity relationships and therapeutic implications. Bone Miner. (1994) 8:265-306.
64. RAVN P, CLEMMESEN B, RIIS BJ et al: The effect on bone mass and bone markers of different doses of ibandronate-a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis-a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone (1996) 19:527-533.
65. ARDEN-CORDONE M, SIRIS ES, LYLES KW et al: Antire-sorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone. Calcif. Tissue Int. (1997) 60:415-8.
66. GREEN JR, MULLER K, JAEGGI KA: Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J. Bone Miner. Res. (1994) 9:745-51.
67. KUDO M, ABE T, MOTOIE H et al: Pharmacological profile of new bisphosphonate, 1-hydroxy-2-(imidazo[1,2-A]pyridin-3-yl)ethane-1,1-bis- (phosphonic acid). Bone Miner. (1992) 17:170.
68. FIDIA ADVANCED BIOPOLYMERS' (FAB) HYALURON RESEARCH: Scrip (1993) 1855:11.
69. ROCHIRAM, MIGLIETTAMR, RICHARDSONJLetal.:Novel vaginal delivery systems for calcitonin. 2. Preparation and characterization of Hyaff microspheres containing calcitonin. Int. J. Pharm. (1996) 144:19-26.
70. RICHARDSON JL, RAMIRES PA, MIGLIETTA MR et al: Novel vaginal delivery systems for calcitonin. 1. Evaluation of Hyaff calcitonin microspheres in rats. Int. J. Pharm. (1995) 115:9-15.
71. MAKINO Y, DOHI M, NISHIBE Y et al: Powder prepara tion of salmon calcitonin for nasal administration. Pharm. Res. (1995) 12:S313.
72. ADACHI JD, BENSEN WG, BELL MJ et al: Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. Br. J. Rheumatol. (1997) 36:255-259.
73. REGINSTER JY, JUPSIN I, DEROISY R et al.: Prevention of postmenopausal bone loss by rectal calcitonin. Calcif. Tissue Int. (1995) 56:539-542.
74. KOLLERUP G, HERMANN AP, BRIXEN K et al.: Effects of salmon calcitonin suppositories on bone mass and turnover in established osteoporosis. Calcif. Tissue Int. (1994) 54:12-15.
75. MAZZANTINI M, DI MUNNO O, PARDINI N et al.: Treatment of postmenopausal osteoporosis with salmon calcitonin suppositories. Ital. J. Miner. Electrolyte Metab. (1996) 10:23-28.
76. MINEGISHI T, NAKAO Y, URADA K et al.: Pharmacological studies of avicatonin ([Asu1,7]-chicken calcitonin). Effects of avicatonin on experimental osteoporosis in rats. Jpn. Pharmacol. Ther. (1994) 22:151-156.
77. HAKEDA Y, KURIHARA N, ARAI Y et al.: Effects of avicatonin (synthetic [Asu1,7] chicken calcitonin) on bone resorption. Avicatonin inhibits generation of multinucleated osteoclast-like cells and their activities. Jpn. Pharmacol. Ther. (1994) 22:143-150.
78. HIDAKA S, ABE K, TAKEUCHI Y et al.: Inhibition of the formation of oral calcium phosphate precipitates: Beneficial effects of Chinese traditional (kampo) medicines. J. Periodont. Res. (1993) 28:27-34.
79. ITABASHI A, NEMOTO K, TSUBOI M et al.: A newly formulated eel calcitonin nasal spray (NDE-1003) has remarkable absorbability and inhibits osteoclastic bone resorption in human. J. Bone Miner. Res. (1997) 12:T546.
80. DEROISY R, COLLETTE J, CHEVALLIER T et al.: Effects of two 1-year calcium and vitamin D3 treatments onbone remodeling markers and femoral bone density in elderly women. Curr. Ther. Res. Clin. Exp. (1998) 59:850-862.
81. KIRIYAMA T, OKAMOTO S, EJIMA E et al.: Effect of a highly potent fluoro analog of 1,25-dihydroxyvitamin D3 on human bone-derived cells. Endocrinol. (1991) 128:81-6.
82. HARADA M, MIYAHARA T, MIYATA M et al.: Effects on cultured neonatal mouse calvaria of 1 alpha, 25-dihydroxyvitamin D3 26,26,26,27,27,27-hexa-fluoro-1 alpha,25-dihydroxyvitamin-D3 and 26,26,26,27,27,27-hexafluoro-1alpha,23S,25- trihydroxyvitamin D3. Bone Miner. (1992) 18:41-49.
83. OKUMURE H, YAMAMURO T, HIGUCHI S et al.: 26,27-Hexafluoro-1,25- dihydroxyvitamin D3 (F6-1,25(OH)2D3) prevents osteoporosis induced by immobilization combined with ovariectomyin the rat. Bone Miner. (1990) 9:101-109.
84. NISHII Y, SATO K, KOBAYASHI T: The development of vitamin D3 analogues for the treatment of osteoporosis. Osteoporos. Int. (1993) 3(Suppl. 1):190-193.
85. TSURUKAMI H, NAKAMURA T, SUZUKI K et al.: A novel synthetic vitamin D analogue, 2 beta-(3-hydroxy-propoxy)1 alpha, 25-dihydroxyvitamin D3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats. Calcif. Tissue Int. (1994) 54:142-9.
86. FUJITA T, INOUE T, MORII H etal: Effect of an intermit tent weekly dose of human parathyroid hormone (1-34) on osteoporosis: a randomized double-masked prospective study using three dose levels. Osteoporosis. Int. (1999) 9:296-306.
87. HODSMAN AB, DROST D, FRAHER LJ etal: The addition of a raloxifene analog (LY117018) allows for reduced PTH(1-34) dosing during reversal of osteopenia in ovariectomized rats. J. Bone Miner. Res. (1999) 14:675-679.
88. LINDSAY R, HODSMAN A, GENANT H et al.: A randomized controlled multi-center study of 1-84 hPTH for treatment of postmenopausal osteoporosis. J. Bone Miner. Res. (1998) 23(Suppl. 5):S175.
89. Hoechst and Biopharm sign bone morphogenetic protein (BMP) deal. Scrip (1994) 1975:11
90. SIMONET WS, LACEYDL, DUNSTAN CR etal.: Osteoprote-gerin-a novel secreted protein involved in the regulation of bone density. Cell (1997) 89:309-319.
91. YASUDA H, SHIMA N, NAKAGAWA N et al: Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG)-a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinol. (1998) 139:1329-1337.
92. BEKKER PJ, HOLLOWAY D, NAKANISHI A et al.: Osteoprotegerin (OPG) has potent and sustained anti-resorptive activity in postmenopausal women. J. Bone Miner. Res. (1999) 14(Suppl. 1):S180.
93. BAGI CM, BROMMAGE R, DELEON L et al.: Benefit of systemically administered rhIGF-I and rhIGF-I/IGFBP-3 on cancellous bone in ovariectomized rats. J. Bone Miner. Res. (1994) 9:1301-1312.
94. BAGI CM, DELEON E, BROMMAGE R et al.: Systemic administration of rhIGF-I or rhIGF-I/IGFBP-3 increases cortical bone and lean body mass in ovariectomized rats. Bone (1995) 16(Suppl. 4):S263-S269.
95. MEUNIER PJ, SLOSMAN D, DELMAS PD et al.: Strontium ranelate as a treatment of vertebral osteoporosis. J. Bone Miner. Res. (1997) 12:S129.
96. vP3 integrin 'vitronectin receptor'. Int. J. Biochem. Cell Biol. (1997) 29:721-725
97. DRAKE FH, DODDS RA, JAMES IE etal: Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J. Biol. Chem. (1996) 271:12511-12516.
98. GARNERO P, BOREL O, BYRJALSENI etal: The collageno-lytic activity of cathepsin K is unique among mammalian proteinases. J. Biol. Chem. (1998) 273:32347-32352.
99. LJUSBERG J, DODDS RA, LARK MW et al: Tartarate-resistant acid phosphatase is proteolytically cleaved in vivo by cathepsin K. J. Bone Miner. Res. (1999) 14(Suppl. 1):S358.
100. XIA L, KILB J, WEX H etal: Localization of rat cathepsin K in osteoclasts and resorption pits: inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl sulfones. Biol. Chem. (1999) 380:679-687.
101. GELB BD, SHI GP, CHAPMAN HA et al.: Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science (1996) 273:1236-1238.
102. JOHNSON MR, POLYMEROPOULOS MH, VOS HL et al.: A nonsense mutation in the cathepsin K gene observed in a family with pycnodysostosis. Genome Res. (1996) 6:1050-1055.
103. SAFTIG P, HUNZIKER E, WEHMEYER O et al.: Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl. Acad. Sci. USA (1998) 95:13453-13458.
104. GOWEN M, LAZNER F, DODDS R et al.: Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J. Bone Miner. Res. (1999) 14:1654-1663.
105. THOMPSON SK, HALBERT SM, BOSSARD MJ et al.: Design of potent and selective human cathepsin K inhibitors that span the active site. Proc. Natl. Acad. Sci. USA (1997) 94:14249-14254.
106. YASUMA T, OI S, CHOH N et al.: Synthesis of peptide aldehyde derivatives as selective inhibitors of human cathepsinL and their inhibitory effect onbone resorp-tion. J. Med. Chem. (1998) 41:4301-4308.
107. LAITALA T, VAANANEN HK: Inhibition of bone resorp-tion in vitro by antisense RNA and DNA molecules targeted against carbonic anhydraseII ortwo subunits of vacuolar H+-ATPase. J. Clin. Invest. (1994) 93:2311-2318.
108. FARINA C, GAGLIARDI S: Selective inhibitors of the osteoclast vacuolar proton ATPase as novel bone antiresorptive agents. Drug Disc. Today (1999) 4:163-172.
109. VISENTIN L, VALENTE M, DODDS RA et al.: SB-242784, a selective inhibitor of the osteoclast v-H+-ATPase, prevents bone loss in ovariectomized rats. Bone (1998) 23:S181.
110. GAGLIARDI S, NADLER G, CONSOLANDI E et al.: 5-(5,6-Dichloro-2-indolyl)-2- methoxy-2,4-pentadienamides-novel and selective inhibitors of the vacuolar H+-ATPase of osteoclasts with bone antiresorptive activity. J. Med. Chem. (1998) 41:1568-1573.
111. SORIANO P, MONTGOMERY C, GESKE R et al.: Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell (1991) 64:693-702.
112. BOYCE BF, YONEDA T, LOWE C et al.: Requirement of pp60c-Src expression for osteoclasts to form ruffled borders and resorb bone in mice. J. Clin. Invest. (1992) 90:1622-1627.
113. MISSBACH M, JESCHKE M, FEYEN J et al.: A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorptionin vitroandinrodent models in vivo. Bone (1999) 24:437-449.
114. GAMSE R, WIDLER L, MISSBACH M et al.: NVP-AAK980, a novel phenylamino-2-alkylamino-purine derivative, potently inhibits the tyrosine kinase Src and bone resorption. J. Bone Miner. Res. (1999) 14(Suppl. 1):S487.
115. ALOBEIDI FA, WU JJ, LAM KS: Protein tyrosine kinases-structure, substrate specificity, and drug discovery. Biopolymers (1998) 47:197-223.
116. DUONG LT, LAKKAKORPI PT, NAKAMURA I et al.: Pyk2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activated by ligation of alpha(v) beta3 integrin, and phosphorylated by Src kinase. J. Clin. Invest. (1998) 102:881-892.
117. LAKKAKORPI PT, NAKAMURA I, NAGY RM et al.: Stable association of PYK2 and p130(Cas) in osteoclasts and their co-localization in the sealing zone. J. Biol. Chem. (1999) 274:4900-4907.
118. DUONG LT, RODAN GA: Integrin-mediated signaling in the regulation of osteoclast adhesion and activation. Front. Biosci. (1998) 3:757-768.
119. COBB MH, GOLDSMITH EJ: How MAP kinases are regulated. J. Biol. Chem. (1995) 270:14843-14846.
120. LEE JC, LAYDON JT, MCDONNELL PC et al.: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature (1994) 372:739-746.
121. GOWEN M, WOOD DD, IHRIE EJ et al.: An interleukin 1-like factor stimulates bone resorption in vitro. Nature (1983) 306:378-380.
122. KIMBLE RB, VANNICE JL, BLOEDOW DC et al.: Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. J. Clin. Invest. (1994) 93:1959-1967.
123. MANOLAGAS SC: Role of cytokines in bone resorption. Bone (1995) 17(Suppl. 2):63S-67S.
124. BADGER AM, BRADBEER JN, VOTTA B et al.: Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharmacol. Exp. Ther. (1996) 279:1453-1461.
125. BRADBEER JN, STROUP GB, HOFFMAN SJ et al.: An orally active inhibitor of cytokine synthesis prevents bone loss in the ovariectomized rat. J. Bone Miner. Res. (1996) 11(Suppl. 1):S125.
126. HENRY JR, RUPERT KC, DODD JH et al.: 6-Amino-2-(4-fluorophenyl)-4- methoxy-3-(4-pyridyl)-1H-pyrrolo[2, 3-b]pyridine (RWJ 68354): a potent and selective p38 kinase inhibitor. J. Med. Chem. (1998) 41:4196-4198.
127. DE LASZLO SE, VISCO D, AGARWAL L et al.: Pyrroles and other heterocycles as inhibitors of p38 kinase. Bioorg. Med. Chem. Lett. (1998) 8:2689-2694.
128. LEE JC, KASSIS S, KUMAR S et al.: p38 mitogen-activated protein kinase inhibitors-Mechanism and therapeutic potentials. Pharmacol. Ther. (1999) 82:389-397.
129. AURON PE: The interleukin 1 receptor: ligand interactions and signal transduction. Cytokine Growth Factor Rev. (1998) 9:221-237.
130. PACIFICI R, VANNICE JL, RIFAS L et al.: Monocytic secretion of interleukin-1 receptor antagonist in normal and osteoporotic women: effects of menopause and estrogen/progesterone therapy. J. Clin. Endocrinol. Metab. (1993) 77:1135-1141.
131. SUNYER T, LEWIS J, OSDOBY P: Estrogen decreases the steady state levels of the IL-1 signaling receptor (Type I) while increasing those of the IL-1decoy receptor (Type II) mRNA in human osteoclast-like cells. J. Bone Miner. Res. (1997) 12 (Suppl. 1):S135.
132. LORENZO JA, NAPRTA A, RAO Y et al.: Mice lacking the Type I interleukin-1 receptor do not lose bone mass after ovariectomy. Endocrinology (1998) 139:3022-3025.
133. TSUDA E, GOTO M, MOCHIZUKI S et al.: Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun. (1997) 234:137-142.
134. BUCAY N, SAROSI I, DUNSTAN CR et al.: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. (1998) 12:1260-1268.
135. LACEY DL, TIMMS E, TAN HL et al.: Osteoprotegerin ligand is a cytokine that regulates osteoclast differen tiation and activation. Cell (1998) 93:165-176.
136. YASUDA H, SHIMA N, NAKAGAWA N et al.: Osteoclast differentiation factor is a ligand for osteoprotegerin osteoclastogenesis-Inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA (1998) 95:3597-3602.
137. WONG BR, JOSIEN R, CHOI Y: TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J. Leukoc. Biol. (1999) 65:715-724.
138. HSU HL, LACEY DL, DUNSTAN CR etal: Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA (1999) 96:3540-3545.
139. MORONY S, CAPPARELLI C, LEE R etal: A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1p, TNFa, PTH, PTHrP, and 1,25(OH)2 D3. J. Bone Miner. Res. (1999) 14:1478-1485.
140. EMERY JG, MCDONNELL P, BURKE MB etal: Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. (1998) 273:14363-14367.
141. KONG YY, YOSHIDA H, SAROSI I et al: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 397:315-323.
142. NEMETH EF: Calcium receptors as novel drug targets. In: Principles of Bone Biology. Bilezekian JP, Raisz LG, Rodan G (Eds.) Academic Press, San Diego, USA (1996):1019-1035.
143. GOWEN M, STROUP GB, DODDS RA etal: Antagonism of the parathyroid Ca++ receptor with a calcilytic compound induces PTH secretion and stimulates bone formation in osteopenic rats. (1999) (Submitted).
144. GOWEN M, STROUP GB, BRADBEER JN etal: An antagonist of the parathyroid cell Ca++ receptor stimulates PTH secretion and bone turnover in osteopenic ovariectomized rats. Bone (1998) 23(Suppl. 5):S163.
145. NEMETH EF, FOX J, DELMAR EG et al.: Stimulation of parathyroid hormone secretion by a small molecule antagonist of the calcium receptor. Bone (1998) 23(Suppl. 5):S156.
146. SCHMITT JM, HWANG K, WINN SR et al: Bone morpho-genetic proteins: an update on basic biology and clinical relevance.J. Orthop. Res. (1999) 17:269-278.
147. NOTOYA K, NAGAI H, ODA T et al: Enhancement of osteogenesis in vitro and in vivo by a novel osteoblast differentiation promoting compound, TAK-778. J. Pharmacol. Exp. Ther (1999) 290:1054-64.
148. WANG GJ, CHUNG KC, SHEN WJ: Lipid clearing agents in steroid-induced osteoporosis. J. Formos. Med. Assoc. (1995) 94:589-592.
149. CUI QJ, WANG GJ, SU CC et al.: Lovastatin prevents steroid induced adipogenesis and osteonecrosis. Clin. Orthop. Rel. Res. (1997) :8-19.
150. FISHER JE, ROGERS MJ, HALASY JM et al.: Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc. Natl. Acad. Sci. USA (1999) 96:133-138.
151. SATO T, MORITA I, MUROTA S: Involvement of cholesterol in osteoclast-like cell formation via cellular fusion. Bone (1998) 23:135-140.
152. MUNDY G, GARRETT R, HARRIS S et al.: Stimulation of bone formation in vitro and in rodents by statins. Science (1999) 286:1946-1949.
153. BAUER DC, MUNDY GR, JAMAL SA et al.: Statin use, bone mass and fracture: an analysis of two prospective studies. J. Bone Miner. Res. (1999) 14(Suppl. 1):S179.
154. TAM CS, AKHTER MP, JOHNSTON E et al.: A new peptide for bone formation with its actions related to exercise. Bone (1998) 23(Suppl. 5):S613.